Group 1 - Longjiang Transportation plans to reduce its shareholding by no more than 3% of the company's total shares, amounting to 39.4764 million shares, from June 4, 2025, to September 3, 2025 [1] - Shuangyi Technology intends to acquire 100% equity of Marky Industries Pty Ltd and specific assets for approximately AUD 18 million [1] - Haikong Air Conditioning's controlling shareholder has received a bank loan commitment of up to CNY 32 million for share repurchase [2] Group 2 - Zhaowei Electromechanical's shareholder plans to reduce its stake by no more than 1.50%, equating to 3.6031 million shares, from June 5, 2025, to September 4, 2025 [2] - Zhongwen Online's directors and senior management plan to collectively reduce their holdings by no more than 877,100 shares, representing 0.1203% of the total shares [2] - Liding Optoelectronics' shareholders plan to reduce their holdings by no more than 3%, totaling 12.2113 million shares, from June 5, 2025, to September 4, 2025 [4] Group 3 - Luvi Optoelectronics' shareholder plans to reduce its stake by no more than 1%, amounting to 1.9333 million shares, from June 4, 2025, to September 4, 2025 [5] - Jiejia Weichuang's controlling shareholder and concerted parties plan to reduce their holdings by no more than 0.72%, totaling 250,000 shares [7] - Yancoal Energy will no longer acquire control of Highfield Resources due to a new investment from Qinghai Salt Lake Industry Co., Ltd. [9] Group 4 - Yongdong Co., Ltd. plans to reduce its shareholding by no more than 1.26%, equating to 473,380 shares, from June 5, 2025, to September 4, 2025 [11] - Sanqi Interactive Entertainment plans to distribute a cash dividend of CNY 2.10 per 10 shares [12] - Salt Lake Co., Ltd. intends to acquire Highfield Resources for approximately USD 300 million to become its largest shareholder [13] Group 5 - Hainan Haiyao's shareholder plans to reduce its stake by no more than 3%, totaling 38.921 million shares, within 90 days after the announcement [14] - Lifang Pharmaceutical plans to transfer 2.2184% equity of Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for CNY 22.1837 million [16] - Zhiyou Technology's shareholders plan to reduce their holdings by no more than 2.99%, totaling 11.9986 million shares, from June 4, 2025, to September 3, 2025 [18] Group 6 - Puli Tui has applied for a review of the Shenzhen Stock Exchange's decision to terminate its listing [19] - Saimo Intelligent's shareholder plans to reduce its stake by no more than 3%, equating to 16.0659 million shares, from June 4, 2025, to September 3, 2025 [20] - Entropy Technology is planning to acquire 55% equity of Longzhiyuan to gain control [21] Group 7 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Process Equipment Manufacturing Co., Ltd. through asset swaps and cash payments [22] - Beijing Lier intends to invest CNY 200 million in Shanghai Zhenliang Intelligent Technology Co., Ltd. [23]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司向深圳证券交易所申请复核的公告 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日收 到深圳证券交易所（以下简称"深交所"）《关于海南普利制药股份有限公司股 票及可转换公司债券终止上市的决定》（深证上〔2025〕357 号）。深圳证券交易 所决定终止公司股票及可转换公司债券（以下简称"可转债"）上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，退市 整理期为十五个交易日，预计最后交易日期为 2025 年 5 月 21 日。公司股票及 可转债于退市整理期届满的次一交易日摘牌并终止上市。 3. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投 ...

Group 1 - Since May, several companies including *ST Zhongcheng, *ST Renle, *ST Hengli, and *ST Gongzhi have announced receipt of termination of listing advance notice, indicating a trend of companies leaving the capital market [1][3] - As of May 12, 2025, a total of 10 companies have received termination of listing advance notices from the Shanghai and Shenzhen Stock Exchanges, with additional companies like *ST Puli and *ST Xulan also facing similar fates [1][3] - The new delisting regulations have been implemented, leading to the first annual report season under these rules, resulting in multiple companies being warned of delisting risks and several directly delisted [5] Group 2 - *ST Renle reported a net asset of -387 million yuan for 2023 and -404 million yuan for 2024, triggering termination of listing due to financial report issues [3] - *ST Hengli's 2023 net profit was negative, and its revenue was below 100 million yuan, leading to a delisting risk warning [3][4] - *ST Zhongcheng's 2023 net asset was also negative, and its 2024 financial report received a qualified opinion, resulting in a proposed termination of listing [3][4] Group 3 - A total of 9 companies have completed delisting in 2025, with reasons ranging from continuous low stock prices to major violations [6][7] - The companies that have delisted include *ST Meixun, Haitong Securities, and *ST Boxin, among others, with various reasons for their delisting [7][8] - The trend indicates a significant number of companies facing financial difficulties and regulatory challenges, leading to increased scrutiny and potential delisting [10] Group 4 - The Beijing Stock Exchange may see its first delisted company, with Guandao Digital and Yun Chuang Data facing delisting risks due to audit issues [9][10] - Both companies have received audit opinions that could lead to termination of listing if they continue to meet financial delisting criteria in 2025 [10] - A total of 96 companies in the A-share market have been warned of delisting risks due to various financial issues, indicating a broader trend of financial instability among listed companies [10]

Core Viewpoint - The company, Hainan Puli Pharmaceutical Co., Ltd., has announced a potential downward adjustment of the conversion price for its convertible bonds due to the stock price falling below a specified threshold over a recent trading period [1][10]. Group 1: Convertible Bond Details - The company issued 8.5 million convertible bonds with a face value of 100 RMB each, raising a total of 850 million RMB, netting approximately 837.86 million RMB after fees [2][4]. - The conversion period for the bonds started on August 23, 2021, and will last until the bonds mature [4]. - The initial conversion price was set at 46.22 RMB per share, which has been adjusted multiple times due to various corporate actions [6][7]. Group 2: Price Adjustment Conditions - According to the bond's offering document, if the stock price falls below 85% of the conversion price for at least 15 out of 30 consecutive trading days, the board can propose a downward adjustment of the conversion price [10][11]. - As of the period from March 17, 2025, to May 9, 2025, the stock has recorded 10 trading days where the closing price was below 2.55 RMB, indicating a potential trigger for the price adjustment [1][10]. Group 3: Future Implications - If the downward adjustment condition is triggered, the company will follow the necessary procedures for board review and shareholder voting as outlined in the offering document [11][12]. - The company has a timeline for the delisting of its stock, with a trading suspension expected to last for 15 days, concluding on May 21, 2025 [1].

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. announced that its stock and convertible bonds will be delisted, with the delisting period starting on April 28, 2025, and expected to last until May 21, 2025 [1][2][3] Group 1: Delisting Information - The convertible bonds will enter a delisting adjustment period for fifteen trading days, with the last trading date anticipated to be May 21, 2025 [1] - After the delisting, the company's stock and convertible bonds will be managed by the National Equities Exchange and Quotations (NEEQ) in a delisting board for transfer [3] - The Shenzhen Stock Exchange has decided to terminate the listing of the company's stock and convertible bonds as of April 18, 2025 [2] Group 2: Management and Compliance - The company is required to appoint a securities firm to provide services for the transfer of its stock and convertible bonds in the delisting board [3][4] - The company has signed an agreement with Guotai Junan Securities Co., Ltd. to act as the main underwriter for the transfer of its stock and convertible bonds [4] - The appointed underwriter will handle various administrative tasks, including registration and confirmation of shares and bonds in the delisting board [4][5]

| 证券代码：300630 | 证券简称：普利退 公告编号：2025-053 | | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | 海南普利制药股份有限公司 关于可转换公司债券预计触发转股价格向下修正条件的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300630 证券简称：普利退 2、债券代码：123099 债券简称：普利转退 3、转股价格：3.00 元/股 4、转股期限：2021 年 8 月 23 日至 2027 年 2 月 8 日 5、根据《海南普利制药股份有限公司创业板向不特定对象发行可转换公司 债券募集说明书》（以下简称"募集说明书"）规定："在本可转债存续期间， 当海南普利制药股份有限公司（以下简称"公司"）股票在任意连续三十个交易 日中至少有十五个交易日的收盘价低于当期转股价格的 85%时，公司董事会有 权提出转股价格向下修正方案并提交公司股东大会表决。" 自 2025 年 3 月 17 日至 2025 年 5 月 9 日期间，公司股票已有 10 个交易日 的收盘价格低于 ...

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于聘请主办券商的公告 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"）进入退市整理期的起始日为 2025 年 4 月 28 日，退市 整理期为十五个交易日，预计最后交易日期为 2025 年 5 月 21 日。公司股票及 可转债于退市整理期届满的次一交易日摘牌并终止上市。 2. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投资者查 阅《关于可转换公司债券退市整理期间交易安排的通知》（深证上〔2023〕492 号）及《关于完善可转换公司债券投资者适当性管理相关事项的通知（2025 年 修订）》（深证上〔2025〕223 号）。 3. 请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 4. 对于将在股票摘牌后至 ...

New Stock Offerings - ST Xinchao (600777) is in the offer period from April 23, 2025, to May 22, 2025[1] - Puli Tui (300630) has 8 trading days remaining until the last trading day[1] - ST Zhongcheng (300208) is also in the offer period with announcements made on April 29, 2025[1] Trading Alerts - ST Yushun (002289) has reported severe abnormal fluctuations as of April 29, 2025[1] - ST Keli Da (603828) has an announcement dated May 9, 2025, regarding trading alerts[1] - ST Yuan Cheng (603388) has similar trading alerts as of May 9, 2025[1] Market Trends - The report indicates a significant number of stocks under abnormal trading conditions, suggesting increased market volatility[2] - Multiple stocks are approaching their last trading days, indicating potential liquidity issues for investors[1] - The overall trend shows a heightened level of scrutiny on stocks with abnormal fluctuations, which may impact investor confidence[2]

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，预计 最后交易日期为 2025年 5月 21日。公司可转债自 2025年 4月 28日起恢复转股。 3. 公司股票及可转债将在退市整理期交易十五个交易日，截至 2025 年 5 月 7 日公司股票及可转债已交易 5 个交易日，剩余 10 个交易日，交易期满将被 终止上市，敬请投资者审慎投资、注意风险。 4. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投资者查 阅《关于可转换公司债券退市整理期间交易安排的通知》（深证上〔202 ...

Summary of Key Points Core Viewpoint - The A-share market shows a significant number of low-priced stocks, with 63 stocks priced below 2 yuan, indicating a potential area for investment analysis and opportunities in the market [1]. Group 1: Market Overview - As of May 6, the Shanghai Composite Index closed at 3316.11 points, with an average A-share price of 11.34 yuan [1]. - The distribution of high-priced and low-priced stocks is relatively small in the overall A-share market [1]. Group 2: Low-Priced Stocks - Among the 63 stocks priced below 2 yuan, the lowest is *ST Jiayao at 0.21 yuan, followed by *ST Pengbo at 0.62 yuan and Puli Tui at 0.69 yuan [1]. - 41.27% of the low-priced stocks are ST stocks, indicating a significant presence of companies under special treatment [1]. Group 3: Performance of Low-Priced Stocks - Out of the low-priced stocks, 49 stocks experienced an increase in price, with Guangtian Group leading at a rise of 9.94%, followed by Shanzi Gaoke at 6.18% and Baogang Co. at 5.78% [1]. - Conversely, 6 stocks saw a decline, with *ST Sihuan dropping by 5.24%, *ST Jinguang by 4.81%, and *ST Xingguang by 4.79% [1].